Drug prescription pattern for asthma among nigerian doctors in general practice: A cross-sectional survey

Annals of Thoracic Medicine

Volumn 7, Issue 2, 2012, Pages 78-83

  Fawibe, Ademola E ^a   Onyedum, Cajetan C ^b   Sogaolu, Olumide O ^c   Ajayi, A O ^d   Fasae, A J ^e  

^a UNIVERSITY OF ILORIN   (Nigeria)

^b UNIVERSITY OF NIGERIA   (Nigeria)

^c UNIVERSITY OF IBADAN   (Nigeria)

^d UNIVERSITY OF ADO EKITI   (Nigeria)

^e FEDERAL MEDICAL CENTER   (Nigeria)

Author keywords

Asthma; drug prescription; general practitioners; Nigeria

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; METHYLXANTHINE DERIVATIVE; MUCOLYTIC AGENT; SHORT ACTING DRUG; STEROID;

ARTICLE; ASTHMA; DISEASE SEVERITY; FOLLOW UP; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; MEDICAL EDUCATION; NIGERIA; PRACTICE GUIDELINE; PRESCRIPTION; SELF REPORT;

EID: 84859776099     PISSN: 18171737     EISSN: 19983557     Source Type: Journal    
DOI: 10.4103/1817-1737.94524     Document Type: Article

References (28)

1. Global initiative for asthma (GINA). Pocket guide for asthma management and prevention: A pocket guide for physicians and nurses based on the global strategy for asthma management and prevention. Medical communication resources, inc 2008.
2. Murphy KR. Asthma: Versatile treatment for a variable disease. J Asthma 2005;42:149-57.
3. Fanta CH. Asthma. N Engl J Med 2009;300:1002-14.
4. Ait-Khalid N, Enarson DA, Chiang CY, Marks G, Bissell K. Management of asthma: A guide to the essentials of good clinical practice, 3rd ed. Paris, France: International Union Against Tuberculosis and Lung Disease; 2008.
5. Verleden GM, DeVuyst P. Assessment of asthma severity and treatment by GPs in Belgium: An asthma drug utilization research study (ADUR). Respir Med 2002;96:170-7.
6. Jepson G, Butler T, Gregory D, Jones K. Prescribing patterns for asthma by general practitioners in six European countries. Respir Med 2000;94:578-83.
7. Lagerlov P, Veninga CC, Muskova M, Hummers-Pradier E, Lundborg CS, Andrew M, et al. Asthma management in five European countries: Doctors' knowledge, attitudes and prescribing behavior. Eur Respir J 2000;15:25-9.
8. Koffi N, Kouassi B, Ngom AK, Kone MS, Danguy EA. Evaluation of management of asthma African adults, National survey among general physicians from Ivory Coast. Rev Mal Respir 2001;18:531-6.
9. Hussain SF, Zahlid S, Khan JA, Haqqee R. Asthma management by general practitioners in Pakistan. Int J Tuberc Lung Dis 2004;8:414-7.
10. National Population Commission of Nigeria. 2006 Final census results. Available from http://www.population.gov.ng/[Last Accessed on 2011 Feb].
11. Nigerian Health Watch: What hope for the National Health Insurance Scheme in 2010. Available from http://www.nigerianhealthwatch. com/2010/01/what-hope- for-national-health-insurance.html [Last Accessed on 2011 Jan].
12. Parameswaran K, Benda J, Rowe BH. Addition of intravenous aminophylline to β2-agonists in adults with acute severe asthma. Cochrane Database Sys Rev 2000;4:CD002742.
13. Reed CE, Hunt LW. The emergency visit and management of athma. Ann Intern Med 1990;112:801-2.
14. Milgrow H, Bender B. Current issues in the use of theophylline. Am Rev Respr Dis 1993;147:553-9.
15. Lazarus SC. Emergency treatment of asthma. N Engl J Med 2010;363:755-64.
16. Raho D, Alfaro C, Sipsey J, Glowsky MM, Sharma OP. Are intravenous corticosteroids required in status asthmatics? JAMA 1998;260:527-9.
17. Dennis SM, Sharp SJ, Vickers MR, Frost CD, Crompton GK, Barnes PJ, et al. Regular inhaled salbutamol and asthma control: The TRUST randomized trial. Therapy Working Group of the National Asthma Task Force and the MRC General practice Research Framework. Lancet 2000;355:1675-9.
18. Schatz M, Nakahiro R, Crawford W, Mendoza G, Mossen D, Stilbolt TB. Asthma quality-of-care markers using administrative data. Chest 2005;128:1968-73.
19. Wraight JM, Hancox RJ, Herbison GP, Cowan JO, Flannery EM, Taylor DR. Bronchodilator tolerance: The impact of increasing bronchoconstriction. Eur Respir J 2003;21:810-5.
20. Wraight JM, Smith AD, Cowan JO, Flannery EM, Herbison GP, Taylor DR. Adverse effecs of short-acting β-agonists: Potential impact when anti-inflammatory therapy is inadequate. Respirology 2004;9:215-21.
21. VanSchayck CP, Cloosterman SG, Bijl-Hofland ID, Van den Hoogen H, Folgening HT, VanWeel C. Is the increase in bronchial responsiveness or FEV1 shortly after cessation of β2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting β2-agonists. Respir Med 2002;96:155-62.
22. Hancox RJ, Cowan JO, Flannery EM, Herbison GP, Mclachlan CR, Taylor DR. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled β-agonist treatment. Respir Med 2000;94:767-71.
23. Greenstone IR, Ni Chroinin Mn, Masse V, Danish A, Magdalinos H, Zhang X, et al. Combination of inhaled long acting β2-agonists and inhaled steroids versus high dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev 2005;4:ID005533.
24. Masoli M, Weatheral M, Holt S, Bealey R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005;60:730-4.
25. Postma DS, O'Byrne PM, Pedersen S. Comparison of the effect of low-dose Ciclesonide and fixed-dose fluticasone propionate and salmeterol combination on long-term asthma control. Chest 2011;139:311-8.
26. Sarrel EM, Mandelberg A, Cohen HA, Kahan E. Compliance of primary care doctors with asthma guidelines and related education. Isr Med Assoc J 2002;4:403-6.
27. Al-Moamary MS, Al-Hajjaj MS, Idrees MM, Zeitouni MO, Alanezi MO, Al-Jahdali H, et al. The Saudi initiatives for asthma. Ann Thorac Med 2009;4:216-33.
28. Al-Shimemeri A, Al-Ghadeer H, Giridhar H, Al-Jahdali H, Al-moamary M, Khan J, et al. Impact of an extensive asthma education campaign for physicians on their drug prescription practices. Ann Thorac Med 2006;1:20-5.